Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targetting large, under-served medical markets.

Its rapidly advancing clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, product candidates that target conditions affecting millions of people, are poorly treated and represent billion dollar markets.

Vantia Therapeutics was spun out from Ferring Research Ltd in 2008. The product pipeline is driven by its small molecule drug discovery and development capabilities and Vantia Therapeutics' experienced management team.

Vantia Therapeutics' strategy is to develop candidates to Phase II proof-of-concept and then commercialise them through partnerships.

The Company is well funded and backed by specialist life science investors MVM Life Science Partners, SV Life Sciences and Novo A/S.